Daily Respiratory Research Analysis
Three high-impact respiratory studies emerged today: an IPD meta-analysis shows single-gene blood transcripts match multi-gene signatures for detecting subclinical tuberculosis and can outperform IGRAs in high-burden settings; a multicenter cohort identifies day-14 tidal volume during ECMO as an independent mortality predictor in COVID-19 ARDS; and a multicenter study validates bronchial aspirate microRNA ratios as robust ICU survival biomarkers in mechanically ventilated COVID-19 patients.
Summary
Three high-impact respiratory studies emerged today: an IPD meta-analysis shows single-gene blood transcripts match multi-gene signatures for detecting subclinical tuberculosis and can outperform IGRAs in high-burden settings; a multicenter cohort identifies day-14 tidal volume during ECMO as an independent mortality predictor in COVID-19 ARDS; and a multicenter study validates bronchial aspirate microRNA ratios as robust ICU survival biomarkers in mechanically ventilated COVID-19 patients.
Research Themes
- Transcriptomic biomarkers for infectious disease risk stratification
- Ventilation strategy optimization during prolonged ECMO in ARDS
- Mucosal biospecimen microRNA profiling for ICU prognostication
Selected Articles
1. Single-gene transcripts for subclinical tuberculosis: an individual participant data meta-analysis.
Across seven datasets (6544 samples), five single-gene transcripts (BATF2, FCGR1A/B, ANKRD22, GBP2, SERPING1) achieved AUCs of 0.75–0.77, equivalent to the best multi-gene signature for detecting subclinical TB over 12 months. Single-gene tests showed setting-invariant sensitivity and specificity, and decision curve analysis indicated higher net benefit than IGRAs in high-burden settings, while combined testing offered the highest benefit in low-burden settings.
Impact: This work redefines minimal transcriptomic biomarkers for subclinical TB and rigorously benchmarks them against IGRAs, providing a pragmatic pathway toward deployable tests across epidemiologic contexts.
Clinical Implications: In high-burden settings, single-gene blood transcript tests may better guide preventive therapy than IGRAs; in low-burden settings, combining IGRAs with single-gene tests maximizes net benefit when aiming to treat fewer individuals per prevented case.
Key Findings
- Five single-gene transcripts (BATF2, FCGR1A/B, ANKRD22, GBP2, SERPING1) matched the best multi-gene signature with AUC 0.75–0.77 over 12 months.
- IGRA specificity was low in high-burden settings (about 32%), whereas single-gene tests maintained more consistent sensitivity and specificity across settings.
- Decision curve analysis favored single-gene testing in high-burden settings and combined IGRA+single-gene testing in low-burden settings for preventive therapy stratification.
- No transcript met WHO minimum target product profile for TB progression tests, underscoring room for improvement.
Methodological Strengths
- One-stage individual participant data meta-analysis across seven datasets (RNA-seq and qPCR).
- Decision curve analysis provided clinically relevant net-benefit benchmarking versus IGRA.
Limitations
- Despite strong performance, signatures did not meet WHO TPP for TB progression tests.
- Heterogeneity in source datasets and observational designs may introduce spectrum bias.
Future Directions: Prospective, implementation-focused trials in varied burden settings to refine thresholds, evaluate combination strategies with IGRA, and assess real-world impact on preventive therapy outcomes.
BACKGROUND: Translation of blood RNA signatures might be accelerated by identifying biomarkers composed of the minimum number of gene transcripts. We aimed to test the hypothesis that single-gene transcripts provide similar accuracy for detection of subclinical tuberculosis to multi-gene signatures and benchmark their accuracy and clinical utility against interferon-γ release assays (IGRAs). METHODS: For this individual participant data meta-analysis, we searched PubMed from database inception to June 10, 2024, using terms for "tuberculosis", "subclinical", and "RNA" to identify studies in which participants underwent whole-blood RNA sampling with at least 12 months of follow-up for development of clinical tuberculosis. We performed a one-stage individual participant data meta-analysis to compare the accuracy of multi-gene signatures against single-gene transcripts to discriminate individuals with subclinical tuberculosis-defined as asymptomatic prevalent or incident tuberculosis (diagnosed ≥21 days from enrolment, irrespective of symptoms) over a 12-month interval-from individuals who remained disease free. We performed decision curve analysis to evaluate the net benefit of using single-gene transcripts and IGRAs, alone or in combination, to stratify preventive treatment compared with strategies of treating all or no individuals.
2. MicroRNA mapping of bronchial aspirate for molecular phenotyping and prognostication in patients on mechanical ventilation.
In 288 invasively ventilated COVID-19 patients, bronchial aspirate miRNA profiles were reproducible and distinct from other airway samples. The miR-34c-5p/miR-34a-5p ratio robustly predicted ICU survival (HR ≈ 0.17) in discovery and validation cohorts, supporting BAS miRNA phenotyping as a prognostic tool and a window into pathogenic pathways.
Impact: It establishes bronchial aspirate miRNA ratios as robust, reproducible prognostic biomarkers in ventilated patients and validates BAS as a feasible respiratory biospecimen for molecular phenotyping.
Clinical Implications: BAS miRNA ratios could inform risk stratification, guide trial enrichment, and enable mechanism-based therapies in ICU respiratory failure, pending prospective validation and clinical integration.
Key Findings
- BAS miRNA profiling was technically reproducible and showed biospecimen-specific patterns distinct from tracheal aspirate and BAL.
- miR-34c-5p/miR-34a-5p (and miR-34c-5p/miR-125b-5p) ratios inversely associated with ICU survival (discovery HR 0.18 and 0.17; validation HR 0.17).
- Functional analysis linked BAS miRNA signatures to key pathogenic pathways, informing potential therapeutic targets.
Methodological Strengths
- Multicenter cohort with discovery and independent validation phases.
- Predefined RT-qPCR panel and hazard-based prognostic modeling with consistent effect sizes.
Limitations
- COVID-19-specific cohort limits generalizability to non-COVID respiratory failure.
- Observational design; clinical utility not yet tested in interventional decision pathways.
Future Directions: Prospective trials to test BAS miRNA-guided care pathways, cross-disease validation (e.g., non-COVID ARDS), and standardization of BAS collection/assays for clinical adoption.
The application of microRNA (miRNA) profiling in respiratory biospecimens, particularly bronchial aspirate (BAS), remains underexplored. Here, we aimed to validate and refine miRNA quantification in BAS samples to establish its suitability for molecular phenotyping. This was a multicenter study including 288 COVID-19 patients on invasive mechanical ventilation. Respiratory biospecimens included BAS, tracheal aspirate, and bronchoalveolar lavage fluid samples. A predesigned miRNA panel was evaluated using RT-qPCR. Biomarker evaluation and functional assessment were subsequently conducted. An initial technical validation phase corroborated the reproducibility of miRNA profiling in BAS samples. Comparative analyses of miRNA expression profiles across respiratory samples revealed distinct miRNA patterns among biospecimens. In the biomarker analysis, two miRNA ratios, miR-34c-5p/miR-34a-5p and miR-34c-5p/miR-125b-5p, were inversely associated with intensive care unit (ICU) survival (hazard ratio [HR]: 0.18 and 0.17, respectively) during the discovery phase. Risk and survival analyses in the test phase confirmed the reproducibility of the miR-34c-5p/miR-34a-5p ratio (hazard ratio [HR] = 0.17). Functional analyses revealed the utility of miRNA profiling in BAS for identifying pathogenic pathways and developing therapeutic targets. Overall, these findings position miRNA profiling in BAS samples as a valuable approach for biomarker discovery, identification of pathophysiological mechanisms, and development of targeted pulmonary therapies.
3. Tidal volume and mortality during extracorporeal membrane oxygenation for acute respiratory distress syndrome: a multicenter observational cohort study.
In 1137 ECMO-treated COVID-19 ARDS patients, mortality predictors shifted over time: age and lactate at day 1, but by day 14, higher tidal volume (per predicted body weight) independently associated with lower mortality (aOR 0.693 per 1 mL/kg increase). Patients ventilated with <2 mL/kg at day 14 had adjusted mortality exceeding 80%.
Impact: Challenges the dogma of ultra-protective ventilation late during ECMO by identifying day-14 tidal volume as a time-varying independent mortality predictor, informing future ventilation strategies.
Clinical Implications: Reassess ultra-protective ventilation targets in prolonged ECMO; individualized tidal volumes guided by compliance may be reasonable while awaiting prospective interventional trials.
Key Findings
- Overall ICU mortality was 75% in this multicenter ECMO cohort.
- Day-1 mortality model retained age and lactate; by day 14, tidal volume (per PBW) independently predicted mortality (aOR 0.693 per +1 mL/kg).
- Adjusted mortality exceeded 80% when day-14 tidal volume was <2 mL/kg PBW.
- Higher tidal volumes reflected higher respiratory system compliance, though benefits were not uniform in very low driving pressure scenarios.
Methodological Strengths
- Large multicenter cohort (29 centers, n=1137) with day-by-day modeling over the first 14 days.
- Adjusted analyses with stepwise logistic regression; registered study (DRKS00022964).
Limitations
- Retrospective observational design limits causal inference.
- Restricted to COVID-19 ARDS and German centers during 2020–2021 with high overall mortality.
Future Directions: Prospective trials to test ventilation targets during prolonged ECMO, incorporating compliance-guided tidal volume strategies and evaluating patient-centered outcomes.
BACKGROUND: Approximately half of the patients with acute respiratory distress syndrome (ARDS) receiving extracorporeal membrane oxygenation (ECMO) remain ECMO-dependent beyond 14 days after ECMO initiation. The identification of factors associated with mortality during an ECMO run may update prognostic assessment and focus clinical interventions. METHODS: In this observational study, data from 1137 patients with COVID-19 ARDS receiving ECMO support in 29 German centers between January 1st 2020 and July 31st 2021 were analyzed. Multivariable stepwise logistic regression analyses were performed to build survival prediction models with day-by-day data during the first 14 days of an ECMO run. The primary endpoint was all-cause mortality in the intensive care unit. RESULTS: Mortality in this cohort was high (75%). Patients who remained ECMO-dependent on day 14 of their ECMO run showed comparable mortality to all patients receiving ECMO support on day 1. Yet, factors associated with mortality changed during the first 14 days of ECMO support. On day 1 of ECMO support, only patient age and lactate remained in the final mortality prediction model. On day 14 of an ECMO run, tidal volume was independently associated with mortality (adjusted Odds Ratio 0.693 (95%CI 0.564-0.851), p < 0.001 for 1 mL/kg increase in tidal volume per predicted body weight). The adjusted mortality for patients with a tidal volume below 2 mL/kg on day 14 of their ECMO run was above 80% (lower limit of the 95%CI interval). Higher tidal volume was mainly based on higher respiratory system compliance. Yet, the benefit of higher compliance was not observed in some patients who were still ventilated with very low driving pressures despite remaining ECMO-dependent on day 14 of ECMO support. CONCLUSIONS: Mortality predictors change during the course of an ECMO run. In a cohort with high mortality, on day 14 of ECMO support for ARDS, tidal volume may be an independent predictor of mortality. Further analyses on ventilation strategies in patients who remain ECMO-dependent are needed. TRIAL REGISTRATION NUMBER: DRKS00022964, retrospectively registered.